Academic Journal
Q2Clinical Lymphoma Myeloma & Leukemia
About Clinical Lymphoma Myeloma & Leukemia
Clinical Lymphoma Myeloma & Leukemia is a scholarly journal published by Elsevier Inc.. SCImago 2025 places it in Q2 with an SJR of 0.615 and an H-index of 71.
Its listed coverage is 2010-2026 and its research categories include Hematology (Q2); Cancer Research (Q3); Oncology (Q3). The 2025 dataset reports 246 documents and 1413 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research.
Recent Research Articles
Latest publications matched automatically by ISSN.
Table of Contents
2026-09 · DOI: 10.1016/s2152-2650(26)03271-4Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily
Mohammed Abdulgayoom, Motaz Almahmood, Rasha Kaddoura, Rowan Mesilhy et al.
2026-09 · DOI: 10.1016/j.clml.2026.07.001Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Clinical Characteristics, Treatment Patterns, and Survival Outcomes in a Tertiary Care Center Cohort
Ricardo Kosch, Winfried Alsdorf, Paymon Ahmadi, Angelique Hölzemer et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.013SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation
Molly Gilligan, Alexandra Gomez-Arteaga
2026-09 · DOI: 10.1016/j.clml.2026.07.006Second Primary Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Comprehensive Review
Julian J. Guetta-Weiss, Danielle M. Brander
2026-09 · DOI: 10.1016/j.clml.2026.05.012Patient-Reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-Body Injector vs Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma
Gurdeep Parmar, Marcelo Capra, Vania Hungria, Fernanda Salles Seguro et al.
2026-09 · DOI: 10.1016/j.clml.2026.08.019Real-world experience with mogamulizumab for mycosis fungoides and Sézary syndrome
Charalampos Filippatos, Maria Gavriatopoulou, Alexandros Briasoulis, Ioannis Ntanasis-Stathopoulos et al.
2026-09 · DOI: 10.1016/j.clml.2026.08.018Progressive multifocal leukoencephalopathy following bispecific antibody therapy in multiple myeloma: a case series
Tyler B. Sandahl, Morie Gertz, Wilson I. Gonsalves, Vy Huynh et al.
2026-09 · DOI: 10.1016/j.clml.2026.09.001Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma
Taku Kikuchi, Moe Nomura-Yogo, Ukyo Kondo, Shotaro Sugita et al.
2026-09 · DOI: 10.1016/j.clml.2026.07.002SOHO State-of-the-Art Updates and Next Questions: Current Approach to Waldenström Macroglobulinemia
Prashant Kapoor, Udit Yadav, Camille Edwards, Jorge J. Castillo et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.016Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia
Mahesh Swaminathan, Hussein A. Abbas, Michael Roth, Michelle A.T. Hildebrandt et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.011Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes
Samuel Ramos, Shin Zaw, Allison Carilli, Ishak A. Mansi et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.007Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management
Roberto Mina, Evangelos Terpos, Lorenzo Cani, Ajay Nooka et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.014Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN)
Uday Yanamandra, Raja Ramachandran, Vinay Sakhuja, Ranjith Nair et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.006The Influence of Racial, Socioeconomic, and Geographic Disparities in the Survival of Patients With Plasmablastic Lymphoma: A Population-Based Analysis From the Surveillance, Epidemiology, and End Results (SEER) Database (2000-2022)
Shahzaib Maqbool, Mohammad Ebad UR Rehman, Muhammad Ibrahim, Syed Imam Naufil et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.012Letermovir for Cytomegalovirus Prophylaxis in Patients With T-PLL Treated With Alemtuzumab
John C. Reneau, Ying Huang, Zachary Braunstein, Walter Hanel et al.
2026-09 · DOI: 10.1016/j.clml.2026.06.015Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival
Ahmet Yigitbasi, Fulya Oz Puyan, Hakki Onur Kirkizlar, Tugcan Alp Kirkizlar et al.
2026-09 · DOI: 10.1016/j.clml.2026.07.003Editorial Board
2026-09 · DOI: 10.1016/s2152-2650(26)03270-2CLL-1374: Beyond Time to First Treatment: Unmutated IGHV and Bone Marrow Failure–Driven Progression in Chronic Lymphocytic Leukemia
Maria Bacanu, Meilin Omer, Elena Pirvu, Diana Grasu et al.
2026-08 · DOI: 10.1016/s2152-2650(26)02108-7MDS-749: Comparative Efficacy and Safety of Oral Azacitidine (CC-486) Versus Injectable Hypomethylating Agents as Maintenance Therapy Following Allogeneic Haematopoietic Cell Transplantation in Myelodysplastic Neoplasms: A Systematic Review and Network Meta-Analysis
Basil Joy, Joseph Tomy, Ajina Joy, M Abhinav et al.
2026-08 · DOI: 10.1016/s2152-2650(26)02241-xReviews
Community Reviews
Version History
September 8, 2026 at 12:09 am
September 8, 2026